KAMAN LINDGREN: Open Payments
NPI 1811522766 · LACEY, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,209 in 15 payments from 8 companies in 2025. Trend: 2023 $748 · 2024 $1,251 · 2025 $1,209
Food & beverage: $1,131Education: $78
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $630 |
| Adaptive Biotechnologies Corporation | 1 | $163 |
| Alnylam Pharmaceuticals Inc. | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $89 |
| ABBVIE INC. | 3 | $88 |
| Regeneron Healthcare Solutions, Inc. | 1 | $81 |
| BeiGene USA, Inc. | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
Products named: RYBREVANT, clonoSEQ, GIVLAARI, FRUZAQLA, EPKINLY, LIBTAYO, ERLEADA, BRUKINSA.
Industry payments across WA — which companies pay providers there.
